Crossover Comparison of Efficacy and Preference
for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine
by
Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M.
Ottawa Headache Centre, Ottawa, Canada.
Eur Neurol 2003;49(1):20-9

ABSTRACT

Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p /=5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).

TCAs
SSRIs
5-HTP
Triptans
Migraine
Sumatriptan
Zolmitriptan
Moclobemide
Beta-blockers
Antidepressants
Rizatriptan (Maxalt)
Migraine prophylaxis
Venlafaxine/headaches
Triptans, migraine and depression

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family